These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
535 related articles for article (PubMed ID: 29990840)
1. miR-125a-3p is responsible for chemosensitivity in PDAC by inhibiting epithelial-mesenchymal transition via Fyn. Liu G; Ji L; Ke M; Ou Z; Tang N; Li Y Biomed Pharmacother; 2018 Oct; 106():523-531. PubMed ID: 29990840 [TBL] [Abstract][Full Text] [Related]
2. Leptin-elicited miRNA-342-3p potentiates gemcitabine resistance in pancreatic ductal adenocarcinoma. Ma L; Fan Z; Du G; Wang H Biochem Biophys Res Commun; 2019 Feb; 509(3):845-853. PubMed ID: 30638935 [TBL] [Abstract][Full Text] [Related]
3. SNHG14 enhances gemcitabine resistance by sponging miR-101 to stimulate cell autophagy in pancreatic cancer. Zhang X; Zhao P; Wang C; Xin B Biochem Biophys Res Commun; 2019 Mar; 510(4):508-514. PubMed ID: 30737032 [TBL] [Abstract][Full Text] [Related]
4. MiR-125a regulates chemo-sensitivity to gemcitabine in human pancreatic cancer cells through targeting A20. Yao J; Li Z; Wang X; Xu P; Zhao L; Qian J Acta Biochim Biophys Sin (Shanghai); 2016 Feb; 48(2):202-8. PubMed ID: 26758190 [TBL] [Abstract][Full Text] [Related]
5. MicroRNA-34a Alleviates Gemcitabine Resistance in Pancreatic Cancer by Repression of Cancer Stem Cell Renewal. Pan Y; Li K; Tao X; Zhao Y; Chen Q; Li N; Liu J; Go VLW; Guo J; Gao G; Xiao GG Pancreas; 2021 Oct; 50(9):1260-1266. PubMed ID: 34860809 [TBL] [Abstract][Full Text] [Related]
6. miRNA-181b increases the sensitivity of pancreatic ductal adenocarcinoma cells to gemcitabine in vitro and in nude mice by targeting BCL-2. Cai B; An Y; Lv N; Chen J; Tu M; Sun J; Wu P; Wei J; Jiang K; Miao Y Oncol Rep; 2013 May; 29(5):1769-76. PubMed ID: 23440261 [TBL] [Abstract][Full Text] [Related]
7. MicroRNA Profiling Implies New Markers of Gemcitabine Chemoresistance in Mutant p53 Pancreatic Ductal Adenocarcinoma. Dhayat SA; Mardin WA; Seggewiß J; Ströse AJ; Matuszcak C; Hummel R; Senninger N; Mees ST; Haier J PLoS One; 2015; 10(11):e0143755. PubMed ID: 26606261 [TBL] [Abstract][Full Text] [Related]
8. MicroRNA-101-3p reverses gemcitabine resistance by inhibition of ribonucleotide reductase M1 in pancreatic cancer. Fan P; Liu L; Yin Y; Zhao Z; Zhang Y; Amponsah PS; Xiao X; Bauer N; Abukiwan A; Nwaeburu CC; Gladkich J; Gao C; Schemmer P; Gross W; Herr I Cancer Lett; 2016 Apr; 373(1):130-137. PubMed ID: 26828016 [TBL] [Abstract][Full Text] [Related]
9. The role of lncRNA MSC-AS1/miR-29b-3p axis-mediated CDK14 modulation in pancreatic cancer proliferation and Gemcitabine-induced apoptosis. Sun Y; Wang P; Yang W; Shan Y; Zhang Q; Wu H Cancer Biol Ther; 2019; 20(6):729-739. PubMed ID: 30915884 [TBL] [Abstract][Full Text] [Related]
10. MiR-373-3p enhances the chemosensitivity of gemcitabine through cell cycle pathway by targeting CCND2 in pancreatic carcinoma cells. Hu W; Liu Q; Pan J; Sui Z Biomed Pharmacother; 2018 Sep; 105():887-898. PubMed ID: 30021382 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of oncogenic Pim-3 kinase modulates transformed growth and chemosensitizes pancreatic cancer cells to gemcitabine. Xu D; Cobb MG; Gavilano L; Witherspoon SM; Williams D; White CD; Taverna P; Bednarski BK; Kim HJ; Baldwin AS; Baines AT Cancer Biol Ther; 2013 Jun; 14(6):492-501. PubMed ID: 23760491 [TBL] [Abstract][Full Text] [Related]
12. A Novel MIF Signaling Pathway Drives the Malignant Character of Pancreatic Cancer by Targeting NR3C2. Yang S; He P; Wang J; Schetter A; Tang W; Funamizu N; Yanaga K; Uwagawa T; Satoskar AR; Gaedcke J; Bernhardt M; Ghadimi BM; Gaida MM; Bergmann F; Werner J; Ried T; Hanna N; Alexander HR; Hussain SP Cancer Res; 2016 Jul; 76(13):3838-50. PubMed ID: 27197190 [TBL] [Abstract][Full Text] [Related]
13. MiR-301a transcriptionally activated by HIF-2α promotes hypoxia-induced epithelial-mesenchymal transition by targeting TP63 in pancreatic cancer. Zhang KD; Hu B; Cen G; Yang YH; Chen WW; Guo ZY; Wang XF; Zhao Q; Qiu ZJ World J Gastroenterol; 2020 May; 26(19):2349-2373. PubMed ID: 32476798 [TBL] [Abstract][Full Text] [Related]
14. LncRNA TUG1 promoted viability and associated with gemcitabine resistant in pancreatic ductal adenocarcinoma. Yang F; Li X; Zhang L; Cheng L; Li X J Pharmacol Sci; 2018 Jun; 137(2):116-121. PubMed ID: 29960845 [TBL] [Abstract][Full Text] [Related]
15. miR-24-3p Regulates Epithelial-Mesenchymal Transition and the Malignant Phenotype of Pancreatic Adenocarcinoma by Regulating ASF1B Expression. Huang W; Lin T; Huang L; Wu J; Hong J; Qiu F; Tian Y; Wang Y Biochem Genet; 2023 Apr; 61(2):742-761. PubMed ID: 36114946 [TBL] [Abstract][Full Text] [Related]
16. Prolactin receptor potentiates chemotherapy through miRNAs-induced G6PD/TKT inhibition in pancreatic cancer. Liao YN; Huang PQ; Pan H; Gai YZ; Zhan YF; Li SX; Nie HZ FASEB J; 2024 May; 38(10):e23705. PubMed ID: 38805171 [TBL] [Abstract][Full Text] [Related]
17. Simvastatin attenuates macrophage-mediated gemcitabine resistance of pancreatic ductal adenocarcinoma by regulating the TGF-β1/Gfi-1 axis. Xian G; Zhao J; Qin C; Zhang Z; Lin Y; Su Z Cancer Lett; 2017 Jan; 385():65-74. PubMed ID: 27840243 [TBL] [Abstract][Full Text] [Related]
18. Micro-RNA-21 Regulates Cancer-Associated Fibroblast-Mediated Drug Resistance in Pancreatic Cancer. Zhang L; Yao J; Li W; Zhang C Oncol Res; 2018 Jul; 26(6):827-835. PubMed ID: 28477403 [TBL] [Abstract][Full Text] [Related]
20. miR-153 enhances the therapeutic effect of gemcitabine by targeting Snail in pancreatic cancer. Liu F; Liu B; Qian J; Wu G; Li J; Ma Z Acta Biochim Biophys Sin (Shanghai); 2017 Jun; 49(6):520-529. PubMed ID: 28459992 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]